1. Home
  2. CSWC vs MESO Comparison

CSWC vs MESO Comparison

Compare CSWC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSWC
  • MESO
  • Stock Information
  • Founded
  • CSWC 1961
  • MESO 2004
  • Country
  • CSWC United States
  • MESO Australia
  • Employees
  • CSWC N/A
  • MESO N/A
  • Industry
  • CSWC Textiles
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CSWC Consumer Discretionary
  • MESO Health Care
  • Exchange
  • CSWC Nasdaq
  • MESO Nasdaq
  • Market Cap
  • CSWC 1.1B
  • MESO 1.3B
  • IPO Year
  • CSWC N/A
  • MESO N/A
  • Fundamental
  • Price
  • CSWC $20.82
  • MESO $16.73
  • Analyst Decision
  • CSWC Buy
  • MESO Buy
  • Analyst Count
  • CSWC 5
  • MESO 2
  • Target Price
  • CSWC $23.50
  • MESO $24.00
  • AVG Volume (30 Days)
  • CSWC 656.8K
  • MESO 258.9K
  • Earning Date
  • CSWC 11-03-2025
  • MESO 08-28-2025
  • Dividend Yield
  • CSWC 12.24%
  • MESO N/A
  • EPS Growth
  • CSWC N/A
  • MESO N/A
  • EPS
  • CSWC 1.64
  • MESO N/A
  • Revenue
  • CSWC $209,032,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • CSWC $14.60
  • MESO $288.50
  • Revenue Next Year
  • CSWC $10.75
  • MESO $167.17
  • P/E Ratio
  • CSWC $12.71
  • MESO N/A
  • Revenue Growth
  • CSWC 10.52
  • MESO 191.39
  • 52 Week Low
  • CSWC $17.46
  • MESO $7.09
  • 52 Week High
  • CSWC $25.80
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • CSWC 44.82
  • MESO 47.21
  • Support Level
  • CSWC $20.18
  • MESO $16.55
  • Resistance Level
  • CSWC $21.00
  • MESO $18.94
  • Average True Range (ATR)
  • CSWC 0.35
  • MESO 0.52
  • MACD
  • CSWC 0.12
  • MESO -0.25
  • Stochastic Oscillator
  • CSWC 86.50
  • MESO 6.88

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: